A team from the University of Rochester Medical Center has shown scientifically what many women report anecdotally: that the breast cancer drug tamoxifen is toxic to cells of the brain and central nervous system, producing mental fogginess similar to “chemo brain.”However, in the Journal of Neuroscience, researchers also report they’ve discovered an existing drug compound that appears to counteract or rescue brain cells from the adverse effects of the breast cancer drug. D., professor of Biomedical Genetics and director of the UR Stem Cell and Regenerative Medicine Institute, said it’s exciting to potentially be able to prevent a toxic reaction to one of the oldest and most widely used breast cancer medications on the market. Although tamoxifen is more easily tolerated compared to most cancer treatments, it nonetheless produces troubling side effects in a subset of the large number of people who take it. By studying tamoxifen’s impact on central nervous system cell populations and then screening a library of 1,040 compounds already in clinical use or clinical trials, his team identified a substance known as AZD6244, and showed that it essentially eliminated tamoxifen-induced killing of brain cells in mice.“As far as I know, no one else has discovered an agent that singles out and protects brain and central nervous system cells while also not protecting cancer cells,” said Noble, who also collaborates with researchers at the UR's James P. “This creates a whole new paradigm; it’s where we need to go.”The research is the result of two separate but related projects from Noble’s lab. One investigates the science underlying a condition known as “chemo brain,” and another is looking at how to exploit tamoxifen’s attributes for use in other types of cancer besides early-stage, less-aggressive breast cancer. (The drug is a type of hormonal therapy, which works by stopping the growth of estrogen-sensitive tumors.)In the Journal of Neuroscience paper, Noble’s team first identified central nervous system (CNS) cells that are most vulnerable to tamoxifen toxicity. Chief among these were oligodendrocyte-type 2 astrocyte progenitor cells (O-2A/OPCs), cells that are essential for making the insulating sheaths (called myelin) required for nerve cells to work properly. Exposure to clinically relevant levels of tamoxifen for 48 hours killed more than 75 percent of these cells. This content has not been reviewed within the past year and may not represent Web MD's most up-to-date information. To find the most current information, please enter your topic of interest into our search box. " July 19, 2002 -- Chemotherapy may not be necessary for preventing some types of breast cancer from coming back in postmenopausal women. A new report shows treatment with the drug tamoxifen may be enough to prevent recurrence in these women, without the negative side effects that come with chemotherapy. women with breast cancers that have spread to the lymph nodes, the standard therapy includes a short course of chemotherapy followed by treatment with tamoxifen. But other experts say it's still too soon to consider withholding chemotherapy from women who have already suffered from breast cancer once, despite the potential side effects of chemotherapy. Although previous studies have shown that tamoxifen is effective at preventing tumors from coming back in women who have a type of breast cancer that grows when exposed to estrogen (known as estrogen-receptor or ER positive), researchers say there has been little evidence that chemotherapy provides any additional benefit for these women. The study, published in the July 17 issue of the Journal of the National Cancer Institute, involved 1,669 postmenopausal women who had undergone surgery to remove breast cancers that had not spread to the surrounding lymph nodes. To determine the impact of adding chemotherapy to tamoxifen use, the researchers randomly divided the women into two groups. Researchers say about half the women who had surgery for breast cancer between 19 in the U. One group received chemotherapy followed by tamoxifen and the other received tamoxifen alone for five years.
But some cases and weight while tamoxifen is a look at how to the eye that is classified as chemo or. Tamoxifen and chemotherapy. Chemotherapy drug is usually. A team from the University of Rochester Medical Center has shown scientifically what many women report anecdotally that the breast cancer drug tamoxifen.